Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Beta-thalassemia stories

Nov 17, 2026

Marrow raises $173M to develop siRNA alternative to gene therapy for sickle cell

Startup Marrow Therapeutics raised $173 million to develop an siRNA-based infusion therapy for sickle cell disease and beta thalassemia, positioning it as a more accessible alternative to approved one-time CRISPR and gene therapy treatments.

Nov 17, 2026·3 sources
00

Top claims

  • ▪Unlike stem cell gene therapies that require one-time laboratory cell modification, Marrow Therapeutics' MAR-101 can be administered via repeated injections should treatment effects wane
  • ▪Marrow Therapeutics Chief Executive Officer Romesh Subramanian stated that the company is developing MAR-101 to provide a safer, efficacious, and globally accessible treatment alternative for patients with inherited blood disorders
  • ▪Marrow Therapeutics plans to use its $173 million funding to advance its lead drug candidate MAR-101 for sickle cell disease and beta thalassemia and to build out its manufacturing capabilities

Topics

Biotech innovationGene therapyDrug developmentHematologyBiotechnologyBiotech startupGenetic disordersVenture capital funding

Related entities

Sickle Cell disease